The Future of HCV Therapy: With or without Interferon and Ribavirin?

Research output: Chapter in Book/Report/Conference proceedingChapter


The current therapies for hepatitis C, peginterferon plus ribavirin, result in sustained viral response in about 40-50% of HCV genotype 1-infected persons. In practice, the effectiveness of this therapy is further limited by significant side effects of these agents. Fortunately, multiple direct-acting antiviral drugs have entered clinical development for the treatment of chronic hepatitis. In general, these drugs have been identified and selected based on their ability to inhibit critical viral steps in vitro, including NS3/NS4A protease, polymerase, NS5A. The next therapeutic advance in HCV treatment will be protease inhibitors (telaprevir and boceprevir) in combination with peginterferon alfa-2a/2b and ribavirin. Phase II clinical trials clearly demonstrate the essential role of both agents in preventing the emergence of protease inhibitor-resistant virus during therapy and increasing viral eradication. Future approaches to HCV treatment are anticipated to include multiple direct-acting antiviral drugs used in combination to suppress viral replication and prevent resistance. The role of interferon and ribavirin in combination with multiple antivirals remains uncertain but trials are underway.

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Viral Liver Disease
Number of pages7
ISBN (Print)9781405179058
StatePublished - Mar 10 2010


  • Combination therapy
  • HCV
  • Polymerase inhibitor
  • Protease inhibitor

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The Future of HCV Therapy: With or without Interferon and Ribavirin?'. Together they form a unique fingerprint.

Cite this